Strategic partnerships Ochre Bio has a history of high-profile collaborations with Boehringer Ingelheim and a recent large-scale sequencing project with Lexogen, indicating strong receptivity to co-development and outsourcing opportunities in RNA therapies and liver disease solutions.

Executive leadership Recent appointment of a new CEO and a senior independent non-executive director suggests a period of strategic realignment and potential acceleration in fundraising, partnerships, and corporate development activities that sales teams can engage with.

Funding momentum With $40M in investor funding secured and a revenue range of $1M–$10M, Ochre Bio is positioned to scale enabling discussions around larger grant-backed programs, sponsored research, and strategic collaborations to expand liver disease portfolios.

Technology enablement The company leverages AI, computational biology, genomic phenotyping and live human donor liver testing, indicating opportunities to propose advanced data services, AI-driven assays, and integrated bioinformatics collaborations.

Clinical and donor focus Efforts aimed at increasing donor liver supply and reducing cirrhosis complications highlight potential sales for regenerative medicine platforms, cell-based or RNA therapies, and translational research services that align with pharma and hospital systems seeking liver health solutions.